Risk of second primary malignancies after adjuvant chemotherapy
for colon cancer

J 2025

Risk of second primary malignancies after adjuvant chemotherapy for colon cancer

BUCHLER, Tomas; Monika AMBROŽOVÁ; Ondřej MÁJEK; Tereza DIANOVA; Petr KLIKA et al.

Základní údaje

Originální název

Risk of second primary malignancies after adjuvant chemotherapy for colon cancer

Autoři

BUCHLER, Tomas; Monika AMBROŽOVÁ; Ondřej MÁJEK ; Tereza DIANOVA; Petr KLIKA a Ladislav DUŠEK

Vydání

Cancer, Hoboken, Wiley, 2025, 0008-543X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.100 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1002/cncr.70116

UT WoS

001599680900020

EID Scopus

2-s2.0-105018253087

Klíčová slova anglicky

cancer surveillance; chemotherapy; epidemiology; second primary malignancies

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 6. 11. 2025 08:14, Mgr. Tereza Miškechová

Anotace

V originále

Background: Advances in adjuvant chemotherapy have improved survival in patients with stage II-III colon cancer (CC). However, concerns have emerged regarding the risk of second and subsequent primary malignancies (SPMs) based on preclinical data and registry-based studies. This study evaluated the incidence of SPMs among CC survivors in relation to adjuvant chemotherapy type. Methods: This retrospective, population-based cohort study included 18,383 patients with stage II-III CC who were treated between 2010 and 2022. Patients were categorized based on three adjuvant treatments: (1) no chemotherapy, (2) fluorouracil or capecitabine alone, and (3) fluorouracil or capecitabine with oxaliplatin. Standardized incidence ratios (SIRs) for SPMs were calculated using national cancer registry data. Results: In an analysis of all 18,383 patients with stage II and III CC who had up to 11.5 years of follow-up, those who received with fluorouracil or capecitabine plus oxaliplatin had a higher overall risk of SPMs (SIR, 1.5; 95% confidence interval, 1.4-1.6) compared with SIRs of 1.1 (95% confidence interval, 1.0-1.2) in patients who did not receive chemotherapy or who received treatment without oxaliplatin. This elevated risk persisted across both stages and was most pronounced for colorectal SPMs. At 10 years, the cumulative SPM incidence reached 14.6% in the oxaliplatin group versus 12.5% and 11.0% in the other two groups, respectively. Oxaliplatin-treated patients had the highest second CC risk (SIR, 2.2). Conclusions: Oxaliplatin-based adjuvant chemotherapy was associated with a heightened long-term risk of SPMs, particularly second colorectal cancers. These findings highlight the need for risk-adapted survivorship care strategies.

Citovat

BUCHLER, Tomas; Monika AMBROŽOVÁ; Ondřej MÁJEK; Tereza DIANOVA; Petr KLIKA a Ladislav DUŠEK. Risk of second primary malignancies after adjuvant chemotherapy for colon cancer. Cancer. Hoboken: Wiley, 2025, roč. 131, č. 20, s. 1-8. ISSN 0008-543X. Dostupné z: https://doi.org/10.1002/cncr.70116.

@article{2530997,
   author = {Buchler, Tomas and Ambrožová, Monika and Májek, Ondřej and Dianova, Tereza and Klika, Petr and Dušek, Ladislav},
   article_location = {Hoboken},
   article_number = {20},
   doi = {https://doi.org/10.1002/cncr.70116},
   keywords = {cancer surveillance; chemotherapy; epidemiology; second primary malignancies},
   language = {eng},
   issn = {0008-543X},
   journal = {Cancer},
   title = {Risk of second primary malignancies after adjuvant chemotherapy for colon cancer},
   url = {https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.70116},
   volume = {131},
   year = {2025}
}

TY  - JOUR
ID  - 2530997
AU  - Buchler, Tomas - Ambrožová, Monika - Májek, Ondřej - Dianova, Tereza - Klika, Petr - Dušek, Ladislav
PY  - 2025
TI  - Risk of second primary malignancies after adjuvant chemotherapy for colon cancer
JF  - Cancer
VL  - 131
IS  - 20
SP  - 1-8
EP  - 1-8
PB  - Wiley
SN  - 0008543X
KW  - cancer surveillance
KW  - chemotherapy
KW  - epidemiology
KW  - second primary malignancies
UR  - https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.70116
N2  - Background: Advances in adjuvant chemotherapy have improved survival in patients with stage II-III colon cancer (CC). However, concerns have emerged regarding the risk of second and subsequent primary malignancies (SPMs) based on preclinical data and registry-based studies. This study evaluated the incidence of SPMs among CC survivors in relation to adjuvant chemotherapy type. Methods: This retrospective, population-based cohort study included 18,383 patients with stage II-III CC who were treated between 2010 and 2022. Patients were categorized based on three adjuvant treatments: (1) no chemotherapy, (2) fluorouracil or capecitabine alone, and (3) fluorouracil or capecitabine with oxaliplatin. Standardized incidence ratios (SIRs) for SPMs were calculated using national cancer registry data. Results: In an analysis of all 18,383 patients with stage II and III CC who had up to 11.5 years of follow-up, those who received with fluorouracil or capecitabine plus oxaliplatin had a higher overall risk of SPMs (SIR, 1.5; 95% confidence interval, 1.4-1.6) compared with SIRs of 1.1 (95% confidence interval, 1.0-1.2) in patients who did not receive chemotherapy or who received treatment without oxaliplatin. This elevated risk persisted across both stages and was most pronounced for colorectal SPMs. At 10 years, the cumulative SPM incidence reached 14.6% in the oxaliplatin group versus 12.5% and 11.0% in the other two groups, respectively. Oxaliplatin-treated patients had the highest second CC risk (SIR, 2.2). Conclusions: Oxaliplatin-based adjuvant chemotherapy was associated with a heightened long-term risk of SPMs, particularly second colorectal cancers. These findings highlight the need for risk-adapted survivorship care strategies.
ER  -

BUCHLER, Tomas; Monika AMBROŽOVÁ; Ondřej MÁJEK; Tereza DIANOVA; Petr KLIKA a Ladislav DUŠEK. Risk of second primary malignancies after adjuvant chemotherapy for colon cancer. \textit{Cancer}. Hoboken: Wiley, 2025, roč.~131, č.~20, s.~1-8. ISSN~0008-543X. Dostupné z: https://doi.org/10.1002/cncr.70116.

Přehled o publikaci